期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CD8^＋调节性T细胞及其应用的研究进展 被引量：1

The latest advances on the research of CD8^＋ regulatory T lymphocytes
原文传递
导出
摘要 CD8^＋T淋巴细胞的亚群不仅具有细胞毒性作用，还能调节机体的免疫反应。具有免疫抑制作用的CD8^＋调节性T细胞（Tr）能有效阻断过强的免疫应答，维持机体的免疫稳态。随着医学科学的不断发展，近年来对CD8^＋Tr的分型、作用机制及其参与调节自体免疫、器官移植耐受、肿瘤免疫和感染免疫应答等方面的研究取得了巨大进展。 CD8 ^＋ regulatory T lymphocyte （CD8^＋Tr） is a specific T subset with cytotoxic activity, which could actively regulate immune responses. CD8^＋ Tr could suppress unsuitable immune responses and keep the immunological balance of the host. In recent years, a great progress has been made in the study on CD8^＋ Tr including their subgroup, functional mechanism, and the immunoregulatory role in autoimmunity, organ transplantation, tumor, infection immunity.
作者 蔡乃青 彭国平(审校)
机构地区 浙江大学医学院附属第一医院传染病研究所 浙江大学医学院附属第一医院传染病研究所
出处 《国际免疫学杂志》 CAS 2008年第5期353-356,共4页 International Journal of Immunology
基金 省部共建基金项目（WJK-2005-2-040）
关键词 CD8^+T淋巴细胞 调节性T细胞 免疫抑制 CD8 ^＋ T lymphocyte regulatory Tecll Immune inhibition
分类号 R392 [医药卫生—免疫学]
  • 相关文献

参考文献4

二级参考文献91

  • 1杨日东,蔡川川,田广南,黎小东,张文君,陈展琳,梁慕兰.血清固定梅毒患者细胞免疫研究[J].中国实验诊断学,2004,8(5):477-479. 被引量：21
  • 2杨日东,蔡川川,黎小东,田广南,张文君,林仕英,梁慕兰,陈展琳.RPR持续阳性梅毒患者的传染性与细胞免疫的相关性研究[J].中国麻风皮肤病杂志,2005,21(2):93-95. 被引量：14
  • 3[1]Diamond T,Stiel D,Lunzer M,Wilkinson M,Roche J,Posen S.Osteoporosis and skeletal fractures in chronic liver disease.Gut 1990; 31:82-87
  • 4[2]Leslie WD,Bernstein CN,Leboff MS.AGA technical review on osteoporosis in hepatic disorders.Gastroenterology 2003;125:941-966
  • 5[3]van der Merwe SW,van den Bogaerde JB,Goosen C,Maree FF,Milner RJ,Schnitzler CM,Biscardi A,Mesquita JM,Engelbrecht G,Kahn D,Fevery J.Hepatic osteodystrophy in rats results mainly from portasystemic shunting.Gut 2003; 52:580-585
  • 6[4]Kong YY,Feige U,Sarosi I,Bolon B,Tafuri A,Morony S,Capparelli C,Li J,Elliott R,McCabe S,Wong T,Campagnuolo G,Moran E,Bogoch ER,Van G,Nguyen LT,Ohashi PS,Lacey DL,Fish E,Boyle WJ,Penninger JM.Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.Nature 1999; 402:304-309
  • 7[5]Saito K,Ohara N,Hotokezaka H,Fukumoto S,Yuasa K,Naito M,Fujiwara T,Nakayama K.Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.J Biol Chem 2004; 279:13555-13563
  • 8[6]Cenci S,Toraldo G,Weitzmann MN,Roggia C,Gao Y,Qian WP,Sierra O,Pacifici R.Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFNgamma-induced class Ⅱ transactivator.Proc Natl Acad Sci USA2003; 100:10405-10410
  • 9[7]Toraldo G,Roggia C,Qian WP,Pacifici R,Weitzmann MN.IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells.Proc Natl Acad Sci USA 2003; 100:125-130
  • 10[8]Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation.Nature 2003; 423:337-342

共引文献15

同被引文献20

  • 1Morris ES, MacDonald KP, Rowe V, et al. Donor treatment with pe- gyiated G-CSF augments the generation of IL-10-produeing regulatory T cells and promotes transplantation tolerance. Blood, 2004; 103 (9) : 3573 -3581.
  • 2Klangsinslrikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CIM phenotype and a predominance of type 2 dendritic cells. Exp Hemato1,2002; 30 (5) : 495 -501.
  • 3Sun LX, Ren HY, Shi YJ, et al. Recombinant human granulocyte colony-stimulating factor significantly decreases the expression of CX- CP and CCR6 on T cells and preferentially induces T helper cells to a T helper 17 phenotype in peripheral blood harvests. Biol Blood Marrow Transplant,2009 ; 15 (7) :835 - 843.
  • 4Wysocki CA, Jiang Q, Panoskahsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4^ + CD25 ^+ regulatory T cells during acute graft-versus-host disease. Blood,2005 ; 106 (9) : 3300 - 3307.
  • 5Palmer LA, Sale GE, Balogun JI, et al. Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol Blood Marrow Transplant, 2010 ; 16 ( 12 ) : 311 - 319.
  • 6Bogunia-Kubik K, Duda D, Suchnieki K, et al. CCR5 deletion mu- tation and its association with the risk of developing acute graft-ver- sus-host disease after allogeneic hematopoietic stem cell transplanta- tion. Haematologica,2006 ;91 (12) : 1628 - 1634.
  • 7Welniak LA, Wang Z, Sun K,et al. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hema- tol,2004 ;32(3) :318 -324.
  • 8Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. N Engl J Med, 1975; 292(17) :895 -902.
  • 9Chang YJ, Huang XJ. Haploidentieal hematopoietic stem cell trans- plantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curt Opin Hematol, 2012; 19 (6) :454 -461.
  • 10Arberas H, Guardo AC, Bargall6 ME, et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J Antimicrob Chemother, 2013 ;68 (3) :577 - 586.

引证文献1

二级引证文献3

国际免疫学杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部